Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2C6 epitope-based HIV vaccine
- Development stage
- Preclinical
- Lead developer
- University at Buffalo
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
The **2C6 epitope-based HIV vaccine** is a preclinical vaccine candidate designed to elicit protective immune responses against the Human Immunodeficiency Virus (HIV). Developed by researchers at the University at Buffalo (SUNY Buffalo) and its spinout company, POP Biotechnologies, the vaccine targets a highly conserved, cross-clade conformational epitope on the gp41 ectodomain of the HIV envelope glycoprotein (Env). This specific epitope is recognized by the monoclonal antibody 2C6 (76-Q3-2C6), which has been shown to mediate robust antibody-dependent cell cytotoxicity (ADCC) across multiple HIV clades (A through E). The vaccine formulation utilizes a 25-mer peptide representing the 2C6 epitope, displayed on cobalt-porphyrin-phospholipid (CoPoP) liposomes (leveraging POP Biotechnologies' Spontaneous Nanoliposome Antigen Particleization [SNAP] platform) and formulated with saponin-based or squalene adjuvants to enhance immunogenicity and replicate trimer binding.
- Other names
- 2C6 gp41 epitope-based HIV vaccine2C6-based HIV vaccine2C6-based vaccine
02
Targets
NeuraminidaseEnv (HIV-1 envelope glycoprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on 2C6 epitope-based HIV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2C6 epitope-based HIV vaccine.